Related Experiment Video
Updated: Jan 16, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Targeting glypican-3 as a new frontier in liver cancer therapy
Chen-Shiou Wu1, Teng-Yu Lee2,3, Hsu-Wen Chao4,5,6
1Department of Medical Research, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
Abstract:
Glypican-3 (GPC3) is a tumor-associated antigen that is specifically expressed in hepatocellular carcinoma (HCC) and having relatively low levels in normal tissues. This unique expression pattern positions GPC3 as a potential target for precision therapy and drug development in HCC. Recent studies have shown significant advancements in GPC3-targeted therapies and immunotherapies, particularly for patients with advanced or treatment-resistant HCC. Although certain clinical trials have yielded suboptimal results, numerous ongoing studies continue to explore its therapeutic efficacy. This mini-review focuses on the latest research developments regarding GPC3 as a therapeutic target across various HCC treatment strategies, including monoclonal antibodies, bispecific antibodies, chimeric antigen receptor-T-cell therapies, and other innovative approaches. In addition, the limitations of GPC3-targeted therapies and their future application prospects in HCC treatment are discussed. The review particularly emphasizes the unmet need for future research directions, such as combination immunotherapy strategies and novel drug designs. Through the integration of innovative technologies and clinical validation, GPC3 holds strong potential as a promising breakthrough in the treatment of HCC, offering new opportunities for enhancing patient outcomes and improving therapeutic efficacy.
Insights
Glypican-3 (GPC3) is a promising hepatocellular carcinoma (HCC) target. GPC3-targeted therapies, including immunotherapies, show potential for advanced HCC, with ongoing research exploring novel strategies.
Area of Science:
- Oncology
- Immunotherapy
- Biomarkers
Background:
- Glypican-3 (GPC3) is a tumor-associated antigen highly expressed in hepatocellular carcinoma (HCC).
- Its specific expression in HCC and low levels in normal tissues make it an ideal target for precision medicine.
- GPC3's unique profile supports its role in targeted therapy development for HCC.
Purpose of the Study:
- To review the latest advancements in GPC3-targeted therapies for HCC.
- To discuss various treatment strategies including monoclonal antibodies, bispecific antibodies, and CAR-T cell therapies.
- To highlight limitations and future prospects of GPC3-targeted approaches in HCC.
Main Methods:
- Literature review of recent studies on GPC3-targeted therapies.
- Analysis of clinical trial data and ongoing research in HCC treatment.
- Exploration of innovative therapeutic strategies and combination approaches.
Main Results:
- Significant progress has been made in GPC3-targeted therapies and immunotherapies for HCC.
- While some trials show suboptimal results, numerous studies are exploring GPC3's therapeutic efficacy.
- Various approaches like monoclonal antibodies and CAR-T cell therapies are under investigation.
Conclusions:
- GPC3 holds strong potential as a breakthrough target for HCC treatment.
- Future research should focus on combination immunotherapy and novel drug designs.
- Integrating innovative technologies and clinical validation is crucial for enhancing HCC patient outcomes.
